(Q42961191)

11 November 2017

Discordant effects of rasagiline doses in Parkinson disease (English)

1 reference

11 November 2017

1 reference

1 reference

Spyros N Deftereos

1

1 reference

11 November 2017

Christos A Andronis

series ordinal

2

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

11 November 2017

Nature Reviews Neurology

1 reference

11 November 2017

6

1 reference

11 November 2017

7

1 reference

11 November 2017

1p following 410

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.2-c1

11 November 2017

0 references

cites work

Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

Rasagiline in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.2-C1

10.1038/NRNEUROL.2010.2-C1

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference